Abstract
The first publication demonstrating that major depressive disorder (MDD) is associated with alterations in the gut microbiota appeared in 2008 (Maes et al., 2008). The purpose of the present study is to delineate a) the microbiome signature of the phenome of depression, including suicidal behaviours and cognitive deficits; the effects of adverse childhood experiences (ACE) and recurrence of illness index (ROI) on the microbiome; and the microbiome signature of lowered high-density lipoprotein cholesterol (HDLc).
We determined isometric log-ratio abundances or prevalence of gut microbiome phyla, genera, and species by analyzing stool samples from 37 healthy Thai controls and 32 MDD patients using 16S rDNA sequencing.
Six microbiome taxa accounted for 36% of the variance in the depression phenome, namely Hungatella and Fusicatenibacter (positive associations) and Butyricicoccus, Clostridium, Parabacteroides merdae, and Desulfovibrio piger (inverse association). This profile (labeled enterotype 1) indicates compositional dysbiosis, is strongly predicted by ACE and ROI, and is linked to suicidal behaviours. A second enterotype was developed that predicted a decrease in HDLc and an increase in the atherogenic index of plasma (Bifidobacterium, P. merdae, and Romboutsia were positively associated, while Proteobacteria and Clostridium sensu stricto were negatively associated). Together, enterotypes 1 and 2 explained 40.4% of the variance in the depression phenome, and enterotype 1 in conjunction with HDLc explained 39.9% of the variance in current suicidal behaviours.
In conclusion, the microimmuneoxysome is a potential new drug target for the treatment of severe depression and suicidal behaviours, and possibly for the prevention of future episodes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by a Rachadabhisek Research Grant, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, to M.M. The sponsor had no role in the data or manuscript preparation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board (IRB) of Chulalongkorn University, Bangkok, Thailand (IRB no. 62/073), which complies with the International Guideline for Human Research Protection as required by the Declaration of Helsinki. Before taking part in the study, all participants and/or their caregivers provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
emails: Michael Maes: dr.michaelmaes{at}hotmail.com, Asara Vasupanrajit: asara.vasu{at}gmail.com, Ketsupar Jirakran: ket.kett{at}hotmail.com, Pavit Klomkliew: pavit.kw{at}gmail.com, Prangwalai Chanchaem: pc_redseed{at}hotmail.com, Chavit Tunvirachaisakul: Chavit.T{at}chula.ac.th, Kitiporn Plaimas: kplaimas{at}gmail.com, Apichat Suratanee: apichat.s{at}sci.kmutnb.ac.th, Sunchai Payungporn: sp.medbiochemcu{at}gmail.com
Data Availability
The dataset generated during and/or analyzed during the current study will be available from MM upon reasonable request and once the authors have fully exploited the dataset.
